StockMirror — Stock Screener

DIVISLAB Q4 FY26 Results & Earnings Analysis

Sentiment: Neutral (Confidence: high)

Earnings Summary

Divi's Laboratories reported a solid FY26 with 14% total income growth and 17% PAT growth, driven by steady generic volumes and a robust CS pipeline, despite geopolitical supply disruptions and generic pricing pressure. Management guided for double-digit revenue growth in FY27 but provided a cautious 'stable' margin outlook due to cost inflation. Long-term investments in peptides and contrast media are progressing, with several validations completed and commercialization expected within 1-2 years pending customer approvals. The Q&A revealed cautious optimism, with proactive risk management on supply chain and cost pass-through mechanisms in place. Investors should monitor geopolitical developments, customer regulatory timelines for new capacities, and margin trends closely.

Management Tone

Revenue Growth Drivers

Growth vs Margin Focus

Management aims for double-digit revenue growth while maintaining stable margins around current levels (32% EBITDA margin implied). They invest in long-term capacities but are cautious on margin expansion given cost pressures. ,

About Divi's Laboratories Limited

Divi's Laboratories Limited (DIVISLAB) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.

Explore More